Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
171 studies found for:    stem cell transplant | Open Studies | NIH, U.S. Fed
Show Display Options
Rank Status Study
1 Recruiting Effectiveness of a Stress Reduction Intervention in Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
Conditions: Stress;   Family Caregivers
Intervention: Other: Stress Reduction
2 Recruiting Safety Study of Cord Blood Units for Stem Cell Transplants
Conditions: Aplastic Anemia;   Leukemia;   Myelodysplastic Syndrome (MDS);   Lymphoma
Intervention: Procedure: Cord Blood Units
3 Recruiting Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
Conditions: Graft Versus Host Disease;   Hematopoietic/Lymphoid Cancer
Interventions: Drug: fludarabine phosphate;   Drug: busulfan;   Drug: cyclophosphamide;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil
4 Recruiting Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Conditions: GATA2;   Immunodeficiency;   MDS
Interventions: Procedure: Allogeneic HSC;   Drug: Busulfan Test dose;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Busulfan (Busulfex);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Equine Anti-Thymocyte Globulin
5 Recruiting Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency
Condition: DOCK8 Deficiency
Interventions: Procedure: Reduced-intensity hematopoietic stem cell;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Busulfan (Busulfex)
6 Recruiting 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation;   Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
7 Recruiting Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
Conditions: Graft vs Leukemia;   Graft vs Host Disease
Intervention:
8 Recruiting Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans
Conditions: Bronchiolitis Obliterans;   Constructive Bronchiolitis;   Graft Versus Host Disease
Intervention: Drug: Inhaled Cyclosporine Solution
9 Recruiting Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Conditions: Activated B-Cell-Like Diffuse Large B-Cell Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Placebo
10 Recruiting Incidence and Factors Associated With the Development and Severity of Oral Mucositis
Condition: Peripheral Blood Stem Cell Transplantation
Intervention: Other: Mucositis and nutritional assessments
11 Recruiting Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans
Conditions: Bronchiolitis Obliterans;   Graft vs Host Disease
Intervention: Drug: Cyclosporine Inhalation Solution
12 Recruiting Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
Condition: Multiple Myeloma
Interventions: Procedure: Allogeneic HSCT;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Bortezomib;   Drug: Ixazomib;   Drug: Placebo
13 Recruiting Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
Conditions: Hematopoietic and Lymphoid Cell Neoplasm;   Recurrent Hematologic Malignancy
Interventions: Other: Fructooligosaccharide;   Other: Laboratory Biomarker Analysis
14 Recruiting Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: bortezomib;   Drug: lenalidomide;   Other: laboratory biomarker analysis
15 Not yet recruiting Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Conditions: Adult Burkitt Lymphoma;   Adult Diffuse Large B-Cell Lymphoma;   CD20-Positive Neoplastic Cells Present;   Indolent Adult Non-Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Refractory Mature B-Cell Non-Hodgkin Lymphoma
Interventions: Biological: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein;   Radiation: indium In 111-DOTA-biotin;   Radiation: yttrium Y 90 DOTA-biotin;   Drug: Clearing Agent;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
16 Recruiting Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
Conditions: Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: Campath-1H
17 Recruiting Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: therapeutic allogeneic lymphocytes;   Other: laboratory biomarker analysis
18 Recruiting Early Oral Supplementation in Improving Nutritional Status in Patients Undergoing Hematopoietic Stem Cell Transplant
Condition: Malignant Neoplasm
Interventions: Dietary Supplement: Boost Plus;   Dietary Supplement: Pro-Stat 101;   Dietary Supplement: Milkshake;   Other: daily food diaries
19 Recruiting Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Hodgkin Lymphoma;   Adult Non-Hodgkin Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegaloviral Infection;   Hematopoietic and Lymphoid Cell Neoplasm;   HLA-A*0201 Positive Cells Present;   Myelodysplastic Syndrome;   Adult Lymphoblastic Lymphoma;   Chronic Lymphocytic Leukemia;   Myelofibrosis;   Myeloproliferative Neoplasm
Interventions: Biological: CMVpp65-A*0201 peptide vaccine;   Other: Placebo;   Other: Laboratory Biomarker Analysis
20 Recruiting High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
Conditions: Hematopoietic Cell Transplantation Recipient;   Malignant Neoplasm;   Influenza
Interventions: Biological: Trivalent Influenza Vaccine;   Biological: Quadrivalent Influenza Vaccine;   Other: Laboratory Biomarker Analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.